KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Quest Diagnostics (DGX) over the last 17 years, with Sep 2025 value amounting to $432.0 million.

  • Quest Diagnostics' Cash & Equivalents fell 43.46% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $432.0 million, marking a year-over-year decrease of 43.46%. This contributed to the annual value of $549.0 million for FY2024, which is 19.97% down from last year.
  • Quest Diagnostics' Cash & Equivalents amounted to $432.0 million in Q3 2025, which was up 35.42% from $319.0 million recorded in Q2 2025.
  • Quest Diagnostics' Cash & Equivalents' 5-year high stood at $1.2 billion during Q1 2021, with a 5-year trough of $126.0 million in Q2 2023.
  • For the 3-year period, Quest Diagnostics' Cash & Equivalents averaged around $375.2 million, with its median value being $319.0 million (2025).
  • As far as peak fluctuations go, Quest Diagnostics' Cash & Equivalents plummeted by 84.05% in 2023, and later spiked by 434.27% in 2024.
  • Quest Diagnostics' Cash & Equivalents (Quarterly) stood at $872.0 million in 2021, then crashed by 63.88% to $315.0 million in 2022, then spiked by 117.78% to $686.0 million in 2023, then decreased by 19.97% to $549.0 million in 2024, then slumped by 43.46% to $432.0 million in 2025.
  • Its Cash & Equivalents stands at $432.0 million for Q3 2025, versus $319.0 million for Q2 2025 and $188.0 million for Q1 2025.